What is BioEclipse Therapeutics?
BioEclipse Therapeutics operates at the forefront of medical innovation, specializing in the development of next-generation immunotherapies. The company leverages proprietary allogeneic technology to engineer immune solutions that target solid tumors, a segment representing the vast majority of cancer cases. Through its lead candidates, CRX200 and CRX100, BioEclipse Therapeutics aims to bridge the gap in treatment options for patients with resistant or recurring malignancies. By integrating innate and adaptive immune responses, the firm seeks to provide scalable, cost-effective therapeutic interventions that not only address primary disease but also induce durable, tumor-specific immunity.
How much funding has BioEclipse Therapeutics raised?
BioEclipse Therapeutics has raised a total of $7.7M across 1 funding round:
Other Financing Round
$7.7M
Other Financing Round (2019): $7.7M with participation from Revelis Capital Group , LLC
Key Investors in BioEclipse Therapeutics
Revelis Capital Group, LLC
A private investment firm focused on providing strategic capital to high-growth companies within the healthcare and biotechnology sectors.
What's next for BioEclipse Therapeutics?
With this major enterprise-level funding, BioEclipse Therapeutics is poised to transition into a more aggressive phase of clinical validation and operational scaling. The strategic allocation of this capital will likely focus on advancing its pipeline through rigorous human trials and expanding its manufacturing capabilities for allogeneic cell therapies. As the company navigates the complexities of regulatory approval and market entry, the focus remains on demonstrating the clinical efficacy of its engineered immune platforms. Investors and industry stakeholders will be closely monitoring the progress of CRX200 and CRX100 as the firm works to redefine the standard of care for solid tumor oncology.
See full BioEclipse Therapeutics company page
